Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Improved quality of life with erlotinib in a randomised phase III study
ENSURE, a randomised, phase III study, met its primary endpoint of improved progression-free survival (PFS) with erlotinib vs. gemcitabine/cisplatin in Asian patients with epidermal-growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC).
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.